Come back later: ODAC rejects accelerated approval of neoadjuvant Keytruda in TNBC February 12, 2021Vol.47 No.06By Paul Goldberg
Black History MonthConversation with The Cancer Letter VCU’s Rob Winn reflects on a year of COVID, racial reckoning, and being the sole Black director of an NCI-designated cancer center February 12, 2021Vol.47 No.06By Paul Goldberg
NCI NCI raises paylines, commemorates 50th anniversary of the National Cancer Act of 1971 February 12, 2021Vol.47 No.06By Alexandria Carolan and Matthew Bin Han Ong
Drugs & Targets Enhertu receives FDA approval for HER2-positive gastric adenocarcinomas January 22, 2021Vol.47 No.03
Drugs & Targets Darzalex Faspro receives accelerated approval from FDA for newly diagnosed light chain amyloidosis January 22, 2021Vol.47 No.03
Drugs & Targets FDA grants Priority Review to Opdivo as adjuvant therapy resected esophageal or gastroesophageal junction cancer January 22, 2021Vol.47 No.03
Drugs & Targets FDA grants Priority Review to Opdivo + chemotherapy as first-line treatment in metastatic gastric cancer, GEJC and EAC January 22, 2021Vol.47 No.03
Drugs & Targets FDA updates vinca alkaloid labeling for preparation in intravenous infusion bags only January 22, 2021Vol.47 No.03
Clinical Roundup Cancer-related suicide declined in the U.S. during the past two decades January 22, 2021Vol.47 No.03
Clinical Roundup Pre-surgery chemotherapy is possible for early stage pancreatic cancer patients January 22, 2021Vol.47 No.03
